Study Summary
This trial is testing a new drug to see if it's safe and effective in treating advanced solid tumors. Participants will visit the site regularly and receive treatments, with tests to check safety and cancer progression.
- Stomach Cancer
- Ovarian Cancer
- Cancer
- Prostate Cancer
- Breast Cancer
- Uterine Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Kidney Cancer
- Solid Tumors
- Melanoma
- Esophageal Cancer
- Sarcoma
- Lung Cancer
- Thyroid Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 16 Secondary · Reporting Duration: Through study completion, an average of 1 year
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
KVA12123 Plus Pembrolizumab Dose Expansion
1 of 4
KVA12123 Monotherapy Dose Escalation
1 of 4
KVA12123 Plus Pembrolizumab Dose Escalation
1 of 4
KVA12123 Monotherapy Dose Expansion
1 of 4
Experimental Treatment
314 Total Participants · 4 Treatment Groups
Primary Treatment: KVA12123 Plus Pembrolizumab Dose Expansion · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 17 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still opportunities to partake in this study?
"Affirmative, the study is currently seeking enrollees. The trial was initially posted on March 3rd 2023 and has since been updated on the same date. It requires 314 individuals to be recruited from 2 different medical facilities." - Anonymous Online Contributor
What is the aggregate amount of participants involved in this experiment?
"Affirmative. The clinical trial's webpage on clinicaltrials.gov attests to its active recruitment of participants, which began on March 3rd 2023 and was last updated the same day. It is currently looking for 314 individuals from 2 separate sites." - Anonymous Online Contributor
What is the fundamental purpose of this trial?
"This clinical experiment will be assessing the RP2D or MTD of a drug over one year as its primary outcome. Additionally, secondary goals are to measure partial response in patients, peak serum concentration time (tmax), and change from baseline anti-KVA12123 antibodies in serum concentrations." - Anonymous Online Contributor